Paricalcitol

Chemical formula: C₂₇H₄₄O₃ Molecular mass: 416.637 g/mol PubChem compound: 5281104

Therapeutic indications

Paricalcitol is indicated for:

Secondary hyperparathyroidism associated with chronic kidney disease Stages 3 and 4

Population group: only adults (18 years old or older)

Paricalcitol is indicated for the prevention of secondary hyperparathyroidism associated with chronic kidney disease Stages 3 and 4.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

1-2 ug once daily

2-4 ug every 2 days

Secondary hyperparathyroidism associated with chronic kidney disease Stages 3 and 4

Population group: only adults (18 years old or older)

Paricalcitol is indicated for the treatment of secondary hyperparathyroidism associated with chronic kidney disease Stages 3 and 4.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

1-2 ug once daily

2-4 ug every 2 days

Secondary hyperparathyroidism associated with chronic kidney disease Stages 3 and 4

Population group: only children (1 year - 12 years old)

Paricalcitol is indicated for the treatment of secondary hyperparathyroidism associated with chronic kidney disease Stages 3 and 4.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

1 ug once daily every 2 days

Secondary hyperparathyroidism associated with chronic kidney disease Stage 5, haemodialysis or peritoneal dialysis

Population group: only adults (18 years old or older)

Paricalcitol is indicated in adult patients for the prevention and treatment of secondary hyperparathyroidism associated with chronic kidney disease Stage 5 in patients who are on haemodialysis or peritoneal dialysis.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

1-32 ug is based on a baseline iPTH level (pg/ml)/60 [(pmol/l)/7]

Secondary hyperparathyroidism associated with chronic kidney disease Stage 5, haemodialysis or peritoneal dialysis

Population group: only adults (18 years old or older)

Paricalcitol is indicated in adult patients for the prevention and treatment of secondary hyperparathyroidism associated with chronic kidney disease Stage 5 in patients who are on haemodialysis or peritoneal dialysis.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

1-32 ug is based on a baseline iPTH level (pg/ml)/60 [(pmol/l)/7]

Contraindications

Paricalcitol is contraindicated in the following cases:

Pregnancy

Pregnancy

Vitamin D toxicity, hypercalcaemia

at least one of

Poisoning by vitamin D
Hypercalcemia

< Previous: Overview

Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈